OneSource Speciality Pharma Limited Results Analysis-Q1FY27

Financial performance and key Operating Metrics (Consolidated) : Operating Revenue for Q1FY27 is Rs. 449 Crs., 37.2% growth YoY, Total Income is Rs. 453 Crs., 36.17% growth YoY, Gross Profit is Rs. 307 Crs., 30.87% growth YoY, EBITDA is Rs. 123 Crs., 31.57% growth YoY, But EBITDA Margin is 27.47% declined by 72 basis points YoY, PBT Rs. 20 Crs. turned profitable from loss of Rs. 4.4 Crs. YoY, PAT Rs. 25 Crs. turned profitable from loss of Rs. 0.18 Crs. YoY. On QoQ basis Operating Revenue is down up by 4.86%, Total Income is also up by 5.23%, Gross Profit is up by 8.78%, EBITDA is up by 31.21%, PBT Rs. 20 Crs. turned profitable from loss of Rs. 0.29 Crs. QoQ, PAT is also up by 443.48%. Revenue growth is due to semaglutide commercial launch, new MSA contracts, and also new customer wins across various businesses. Second cartridge line commercialization is expected in the current quarter, and management claims it will “double our number of sterile days available for production.” Company is going to be expanding both the mammalian as well as microbial capacity.” significant increase in demand for CDMO services globally, especially in biologics, India today has got a very, very insignificant share of this. there will be enough demand for all the new capacity coming in. Management reiterated: “FY28 outlook of $400 million organic revenue as well as EBITDA margins of 40%.”